Mary L Lambert

US Patent:

6998984, Feb 14, 2006

Filed:

Jul 24, 2001

Appl. No.:

09/912264

Inventors:

Jonathan Zittrain - Cambridge MA, US
Shermann Loyall Min - Pacifica CA, US
Zachary Mainen - Cold Spring Harbor NY, US
Mary Wilson Lambert - New York NY, US
David Goetsch - Los Angelos CA, US

International Classification:

G08B 23/00

US Classification:

3405731, 340 76, 34053911, 34081565

Abstract:

A communications system has first and second units whereby, when a user changes the physical state of the first unit, a message is sent to the second unit to cause the second unit to change to the same state. This change in state can be, for example, a physical squeezing movement or a change in color.

US Patent:

7324000, Jan 29, 2008

Filed:

Feb 14, 2006

Appl. No.:

11/353587

Inventors:

Jonathan Zittrain - Cambridge MA, US
Shermann Loyall Min - Pacifica CA, US
Zachary Mainen - Cold Spring Harbor NY, US
Mary Wilson Lambert - New York NY, US
David Goetsch - Los Angeles CA, US

International Classification:

G08B 23/00

US Classification:

3405731, 340 76, 34053911, 455 903, 472133

Abstract:

A communications system has first and second units whereby, when a user changes the physical state of the first unit, a message is sent to the second unit to cause the second unit to change to the same state. This change in state can be, for example, a physical squeezing movement or a change in color.

US Patent:

20130236466, Sep 12, 2013

Filed:

Nov 14, 2012

Appl. No.:

13/676721

Inventors:

William L. Klein - Winetka IL, US
Brett A. Chromy - Danville CA, US
Lei Chang - Westmont IL, US
Mary P. Lambert - San Antonio TX, US
Kirsten L. Viola - Chicago IL, US

Assignee:

NORTHWESTERN UNIVERSITY - Evanston IL

International Classification:

C07K 16/18

US Classification:

4241391, 5303879, 5303873

Abstract:

The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.

US Patent:

20210386879, Dec 16, 2021

Filed:

Aug 25, 2021

Appl. No.:

17/411400

Inventors:

- Evanston IL, US
William L. Klein - Winetka IL, US
Brett A. Chromy - Danville CA, US
Lei Chang - Westmont IL, US
Mary P. Lambert - San Antonio TX, US
Kirsten L. Viola - Chicago IL, US

International Classification:

A61K 51/10
C07K 16/18
G01N 33/68

Abstract:

A method for detecting soluble oligomeric amyloid β in a subject is provided.

US Patent:

20170209604, Jul 27, 2017

Filed:

Apr 11, 2017

Appl. No.:

15/484509

Inventors:

- Evanston IL, US
William L. Klein - Winetka IL, US
Brett A Chromy - Danville CA, US
Lei Chang - Westmont IL, US
Mary P. Lambert - San Antonio TX, US
Kirsten L. Viola - Chicago IL, US

Assignee:

Northwestern University - Evanston IL

International Classification:

A61K 51/10
G01N 33/68
C07K 16/18

Abstract:

A method for detecting soluble oligomeric amyloid β in a subject using, e.g., PET is provided.

US Patent:

20160213794, Jul 28, 2016

Filed:

Mar 29, 2016

Appl. No.:

15/084117

Inventors:

- Evanston IL, US
William L. Klein - Winetka IL, US
Brett A. Chromy - Danville CA, US
Lei Chang - Westmont IL, US
Mary P. Lambert - San Antonio TX, US
Kirsten L. Viola - Chicago IL, US

International Classification:

A61K 51/10

Abstract:

The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.

US Patent:

20140322731, Oct 30, 2014

Filed:

Feb 26, 2014

Appl. No.:

14/190525

Inventors:

- Evanston IL, US
William L. Klein - Winetka IL, US
David W. Summa - Hillsborough CA, US
Brett A. Chromy - Danville CA, US
Lei Chang - Westmont IL, US
Mary P. Lambert - San Antonio TX, US
Kirsten L. Viola - Chicago IL, US
Yue Song Gong - Drexel Hill PA, US

Assignee:

Northwestern University - Evanston IL

International Classification:

G01N 33/68

US Classification:

435 792, 436501, 435 71

Abstract:

The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.